Q-omics provides the consensus-scored MS4A18 profile across patient tissues and cancer cell-line models. MS4A18 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, MS4A18 is differentially expressed in 4, with the highest sampling consensus in LUSC. Additionally, MS4A18 RNA expression shows 6,604 significant pathway-activity associations, with the highest sampling consensus in UCEC. Together, these results highlight THCA, LUSC, and UCEC as cancer lineages where MS4A18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MS4A18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MS4A18 survival associations across molecular data types. MS4A18 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MS4A18 RNA expression–survival associations across cancer types. High MS4A18 expression shows unfavorable associations in THCA, KICH, ACC and KIRC, but favorable associations in LUAD and BRCA. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for MS4A18 RNA expression.
This table summarizes MS4A18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MS4A18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MS4A18 shows lower tumor expression in LUSC and higher tumor expression in PRAD, LUAD and HNSC. The LUSC box plot shows higher MS4A18 RNA expression in normal versus tumor tissue (log2 FC = −0.109, t-test p = .001).
This table shows molecular features associated with MS4A18 in patient tissues and cancer cell lines. In patient samples, MS4A18 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, MS4A18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE.
